Shares of Merck & Co. Inc. MRK slipped 1.46% to $93.35 Wednesday, on what proved to be an all-around mixed trading session ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

The Green Party's new logo is an emoji. The federal party unveiled its new brand, a green dot, on Tuesday on Parliament Hill, possibly weeks before a snap federal election. "The great thing about ...

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

Just like the brand’s logo, the brand’s name is full of meaning, too. In an Instagram video, Meghan explained, “As Ever essentially means ‘as it’s always been,’ and if you’ve ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...